Gao, L., Kaushik, D., Van Tine, B. A., Ingham, M. A., Attia, S., Meyer, C. F., Schwartz, G. K., Maliakal, P., Baird, J. D., Ma, J., Barrett, R., D’Silva, D., O’Keefe, K., & Kong, R. (2024). Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma. Clinical and Translational Science, 17(2). Portico. https://doi.org/10.1111/cts.13709

Hijiya, N., Kapoor, S., Hoch, M., Descamps, L., Dhamal, V., & Torres Cardoso, A. P. (2023). ASC4KIDS: A Multicenter, Open-Label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Chronic Myeloid Leukemia in the Chronic Phase. Blood, 142(Supplement 1), 6387–6387. https://doi.org/10.1182/blood-2023-185535

Mohite, P., Nahar, D., Pawara, R., Alqahtani, T., Eldin, S. M., Mukherje, N., Rahman Mohammad Said Al-Tawaha, A., Iqbal, R., Bawazeer, S., & Ali, I. (2023). Triazolopyridine, a leitmotif of synthetic methods and pharmacological attributes: An extensive review. Arabian Journal of Chemistry, 16(10), 105181. https://doi.org/10.1016/j.arabjc.2023.105181

Ashton, T. D., Dans, M. G., Favuzza, P., Ngo, A., Lehane, A. M., Zhang, X., Qiu, D., Chandra Maity, B., De, N., Schindler, K. A., Yeo, T., Park, H., Uhlemann, A.-C., Churchyard, A., Baum, J., Fidock, D. A., Jarman, K. E., Lowes, K. N., Baud, D., … Sleebs, B. E. (2023). Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4. Journal of Medicinal Chemistry, 66(5), 3540–3565. https://doi.org/10.1021/acs.jmedchem.2c02092

Di Meo, F., Iyer, A., Akama, K., Yu, C., Cheng, R., Cesarano, A., Marino, S., Aljoufi, A., Soni, R., Roda, J. M., Sissons, J., Vu, L. P., Guzman, M. L., Huang, K., Roodman, D. G., & Perna, F. (2022). A Novel Bi-Specific T-Cell Engager Targeting ILT3 Is Potently Effective in Multiple Myeloma. Blood, 140(Supplement 1), 671–672. https://doi.org/10.1182/blood-2022-167584